PRP for knee osteoarthritis: reading selected evidence

The question and scope

For adults with symptomatic knee osteoarthritis, what do selected sources report about intra-articular PRP compared with placebo or other care for pain, function, and joint structure? This brief concerns knee osteoarthritis. It does not extend findings to tendon conditions, other joints, or other uses of PRP.

Sources were checked on October 2, 2026 through targeted searches of PubMed-indexed literature and AAOS and VA/DoD guidance. Selection emphasized a blinded placebo-controlled trial, recent placebo-focused reviews with differing conclusions, and identifiable guidelines. Trial and review summaries below are based on their PubMed abstracts; this was not a full-text systematic review or an independent medical review.

RESTORE: a specific placebo comparison

The 2021 RESTORE trial randomized 288 adults aged at least 50 with mild-to-moderate radiographic medial knee osteoarthritis. Participants received three weekly injections of leukocyte-poor PRP or saline. At 12 months, the trial found no statistically significant between-group difference in its primary pain or medial tibial cartilage-volume outcomes.

Both groups reported pain improvement. The estimated between-group pain difference was −0.4 points on a 0–10 scale, with a 95% confidence interval from −0.9 to 0.2. This result describes the tested regimen and participants; it is neither proof of cartilage regeneration nor an evaluation of every PRP preparation.

Recent reviews reach different interpretations

Auroux and colleagues’ 2025 review included 11 saline-controlled trials with 1,616 participants. It found pain results favoring PRP at three and six months with substantial heterogeneity, but not at 12 months; total WOMAC results favored PRP at three months, but not at six or 12 months. The authors questioned the clinical relevance of the overall benefit.

Bensa and colleagues’ 2025 review included 18 placebo-controlled trials with 1,995 participants. It reported improvements exceeding its clinical-importance thresholds for pain at three and six months and WOMAC at all evaluated time points. Its platelet-concentration subgroup analysis favored higher-concentration preparations. The authors declared no conflicts of interest in that contribution.

These are separate syntheses with different study sets and analytic decisions. Their totals must not be added as though they represent independent patients. A preparation subgroup finding also should not be turned into a patient-specific dose recommendation.

Guidelines put the uncertainty in context

AAOS’s 2021 knee osteoarthritis guideline says PRP may improve pain and function, but grades that recommendation as limited. The 2026 VA/DoD provider summary, recommendation 20, finds insufficient evidence to recommend for or against PRP for persistent knee osteoarthritis pain.

These organizations’ assessments are attributed judgments, not a certainty score produced by this directory. Ask a clinician which recommendation they use, how current it is, and how its scope fits the proposal being discussed.

What the selected evidence leaves unresolved

The practical questions include which preparation, which patients, which comparator, and how long a benefit might last. This selection does not establish that PRP rebuilds cartilage, reliably delays surgery, or is preferable to every other care option. It also does not quantify uncommon or long-term harms.

Full study methods, adverse-event tables, and complete funding disclosures were not independently audited for this brief. Ask the clinician to review the underlying papers when those details affect your decision, rather than treating an abstract or this summary as sufficient.

Use the evidence in a concrete conversation

Bring the preparation name and proposed schedule. Ask which cited population and outcome are the closest match, what would count as a worthwhile improvement for you, and when that outcome would be checked. Request an explanation of risks, alternatives, and the full cost before deciding. A useful plan also states what happens if the hoped-for change does not occur.

Questions to bring

• Which source best matches the preparation you propose?
• How do you interpret the differing trial, review, and guideline findings?
• What outcome, time frame, risks, and costs should guide our discussion?

Sources and editorial context

This reference was compiled from the sources below and has not received independent clinical review. Use it to understand terms and prepare questions for a qualified professional who can consider your circumstances.